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Summary
Nuclear magnetic resonance (NMR) spectroscopy in
solution has evolved into a powerful technique for
structure determination of proteins and nucleic acids.
More recently, a number of NMR-based approaches
have been developed to monitor and characterize in-
termolecular interactions. These approaches offer
unique advantages over other techniques and find
their utility in both structural biology and drug dis-
covery. We will report on basic principles and recent
examples of the application of such NMR methodolo-
gies to characterize protein-protein interactions and
for ligand binding studies and drug discovery.
Introduction
In this manuscript, we wanted to reiterate some of the
principles underlying nuclear magnetic resonance (NMR)-
based techniques that enable the characterization of
intermolecular interactions. Particular emphasis will be
put on the characterization of protein-protein and pro-
tein-ligand interactions and their use in lead discovery
and optimization. The bottom line in most of these ex-
periments is that NMR parameters of either a protein
target (or nucleic acid) or a ligand are different depend-
ing on whether the molecules are isolated in solution or
form a complex. During the past several years, a num-
ber of techniques that are best suited to detect these
differences have been developed. In essence, most of
such techniques can be grouped into two main cate-
gories. In a first, “direct” approach, protein NMR ob-
servables are directly monitored in the presence of a
binder (another macromolecule or a small molecule). A
second approach is based on the so-called “transfer-
red” techniques, in which the changes in nuclear spin
relaxation of a protein or a small molecule are mea-
sured in the presence of a substoichiometric amount of
target. In addition, we will report on methods to detect
enzyme kinetics and inhibition, in which the consump-
tion of a substrate or a cofactor, or the formation of an
enzymatic product, is directly monitored by NMR. The
main advantage of these strategies in the drug discov-
ery process is that even weak binders or inhibitors can
be detected, with a relatively lower incidence of false
positives than any other type of assay. However, despite
NMR laboratory automation, the use of compound mix-
tures and liquid handlers for sample preparation, NMR-
based assays are intrinsically of a low-throughput na-
ture due to the relatively large amounts of target*Correspondence: mpellecchia@burnham.orgneeded and the relatively lengthy experimental time.
Hence, the obvious way to exploit such assays is to
select and screen small, but diverse, libraries of com-
pounds representing “drug-like” building blocks to
identify preferential scaffolds. These initial, weak hits
could subsequently be optimized by using a number of
strategies. This so-called fragment-based approach to
drug discovery [1–12] is becoming more and more pop-
ular given its versatility to tackle more complex sys-
tems for which high-throughput screening techniques
are not as easily applicable, such as protein-protein in-
teractions. We believe that the NMR-based techniques
reported here will play an increasingly important role in
chemical biology and target validation, particularly
when dealing with “unconventional” and/or less char-
acterized drug targets.
NMR-Based Binding Studies that Rely
on the Observation of Protein Resonances
Macromolecular NMR Spectroscopy: A Brief History
The evolution of NMR spectroscopy from an analytical
technique into an alternative approach to X-ray crystal-
lography in the determination of protein and nucleic
acid conformation in solution became possible with the
development of bidimensional [1H, 1H] nuclear Over-
hauser effect spectroscopy (NOESY) [13]. In this key
NMR experiment, short (<5 Å) internuclear distances
between hydrogen nuclei can be measured and directly
used to probe protein conformation in solution. This
area of research evolved into the current field of mod-
ern macromolecular NMR spectroscopy in solution. In
recognition of the tremendous impact of this line of re-
search on the scientific community, Nobel Prizes in
Chemistry were awarded “for [the] contributions to the
development of the methodology of high-resolution
nuclear magnetic resonance (NMR) spectroscopy” to
Prof. Richard R. Ernst [14, 15] in 1991, and to Prof. Kurt
Wüthrich in 2002 “for his development of nuclear mag-
netic resonance spectroscopy for determining the
three-dimensional structure of biological macromole-
cules in solution” [16, 17]. In order to extend these ba-
sic principles and techniques to larger proteins (up to
w40 kDa), where the problem of resonance overlap in
bidimensional NMR experiments becomes insurmount-
able, multidimensional and triple resonance experi-
ments were introduced in the early 90s by Dr. Ad Bax
(National Institutes of Health) [18–21], and soon after by
several other investigators (reviewed in several refer-
ences such as [22–25]). In these experiments, addi-
tional NMR observable nuclei such as 15N and 13C are
exploited. For recombinant proteins that can be ob-
tained from bacterial expression systems (mainly E. coli),
enrichment of protein samples with these nuclei is now
routine. In contrary, labeling proteins in other expres-
sion systems is still too pricey, but great steps in cell-
free expression are being made [26]. By using 3D and
4D triple resonance experiments that exploit magne-
tization transfers between neighboring 1H, 15N, and 13C
nuclei, sequence-specific resonance assignments of
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availability of the assignments for most hydrogen reso-
nances in a protein, internuclear distances are subse-
quently measured via 3D or 4D versions of the 2D [1H,
1H]-NOESY experiment, in which the additional dimen-
sions can be either 15N or 13C, again to ameliorate the
problem of resonance overlap. Following the strategies
pioneered by Wüthrich and coworkers [27, 28], three-
dimensional models of the protein that satisfy these
distance constraints can be generated. Nowadays, iter-
ative resonance assignments and refinements of the
structure can be obtained semiautomatically, enor-
mously reducing the time needed to obtain a structure
by NMR spectroscopy (see, for example, [29–31]).
With the advent of protein labeling and heteronuclear
protein NMR spectroscopy techniques, other studies
become possible. Because nuclear spin relaxation
mechanisms are strictly correlated with local motion,
scientists started to realize that proteins’ overall and
internal motion can be accurately monitored by nuclear
spin relaxation measurements. It turns out that protein
mobility in solution is nonuniform, with a large variety
of rates and types of dynamics. Investigators in several
research laboratories are trying to find a correlation be-
tween this motion and functional aspects of protein
folding and catalysis [22, 23, 32–34].
In the late 90s, another breakthrough in the field
came with the development of the so-called TROSY
(transverse relaxation optimized spectroscopy)-type
techniques [35, 36]. In brief, the technique exploits sim-
ple nuclear spin relaxation physics principles to artifi-
cially increase the relaxation times of 15N, 1H, and, in
some instances, 13C nuclei, a phenomenon that has a
maximum effect at higher magnetic fields. This results
in increasing the resolution of macromolecular spectra
and allows for the study of large macromolecular com-
plexes in which rapid nuclear relaxation poses a seri-
ous obstacle.
Currently, the combination of advances in instrumen-
tation, the use of orientational constraints in partially
oriented media [37, 38], the use of selective 13C,1H-
methyl labeling in otherwise deuterated samples [39,
40], the simultaneous acquisition of multidimensional
experiments [41], the use of segmental labeling tech-
niques [42–45], and the use of TROSY-type experi-
ments have made NMR spectroscopy a very powerful
and efficient tool for structural biology initiatives [46].
Finally, very recent developments in projection spectros-
copy [47–51] enable the reconstruction of a full multi-
dimensional spectrum by recording discrete sets of
lower-dimension projection experiments. Combined with
automated assignment strategies [52], this approach
promises to significantly reduce the time needed for
data collection and analysis.
It did not take much longer for scientists in both in-
dustry and academia to realize that NMR could also
be very useful in monitoring intermolecular interactions
involving other macromolecules or, in particular, a li-
gand (for recent reviews, see also, for example, [10, 53–
56]). Much of the remainder of this article deals with
this subject.
Protein-Protein and Protein-Ligand Interactions:
The Chemical Shift Mapping
Let’s consider the binding of a ligand L to a target mac-
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(1)
In assessing the effects of chemical exchange on a
MR spectrum, the lifetime of a particular conforma-
ional state relates directly to selected NMR parame-
ers. The lifetimes of the free states for the ligand L, τL,
nd the target, τT, can be expressed as functions of the
opulations, p, of the free and bound states:
τL = pL / (koff ∗ pLT) (2)
nd
τT = pT / (koff ∗ pTL), (3)
here pL = [L]/[Lo], pT = [T]/[To], pLT = [TL]/[Lo], and
TL = [TL]/[To], with Lo and To representing the total con-
entrations of ligand and receptor, respectively. kon and
off represent the on- and off-rates, respectively, for the
ormation of the complex TL (see also Equation 6). For
onvenience in discussing exchange effects, a single
ifetime is commonly defined as:
1 / τ = 1 / τTL + 1 / τL = koff ∗ (1 + pTL /pL). (4)
The relative magnitudes of the lifetime τ and the in-
erse of the chemical shift differences between free
nd bound states will affect the appearance of the NMR
pectrum of the protein in the presence of a ligand. In
he system defined by Equation 1, separate resonance
ines for the free and bound ligands will be observed if
he exchange rate is slow on the “chemical shift time-
cale.” That is, if 1/τ is slower than the chemical shift
ifference between the resonances of the bound and
ree ligands in frequency units:
1 / τ < < δ, (5)
here δ = |(δTL − δL)|.
If the exchange rate is fast on the chemical shift
imescale, the chemical shift mapping by stepwise ti-
ration can also provide a measurement of the dissoci-
tion constant (Kd) by correlating the fractional chemi-
al shift change with the total ligand concentration:
Kd = koff / kon = [T][L] / [TL] (6)
At the equilibrium: [TL] = pTo, [T] = (1 − p)[To], and
L] = [Lo] − p[To]. Introducing these relations into Equa-
ion 6, we obtain:
p =
([To] + [Lo] + Kd) − √([To] + [Lo] + Kd)2− 4[Lo][To]
2[To]
(7)
The parameter p represents the fractional population
f bound versus free species at equilibrium, which, for
ast exchanging ligands, is measured as:
p = (δobs− δfree) / (δsat− δfree) (8)
δobs is the observed receptor chemical shift during
he titration, and δfree and δsat are the chemical shifts for
he receptor in the unbound and fully bound (saturated)
tates, respectively. Kd can then be determined by a
onlinear least squares fit of p versus [Lo]. If we use Kd
alues to estimate k values, ligands that bind withoff
dissociation constants greater than 10−5 M will be in
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963the fast exchange limit for chemical shift timescales, if
we assume a diffusion controlled on-rate of w108–109
M−1s−1 . Those in the 10−6–10−7 M range often fall into
the intermediate range between the slow and fast ex-
change limiting situations, and those at 10−8 M or
smaller are usually in the slow exchange limit.
A simple technique that exploits differences in chem-
ical shift between free and bound protein targets is
based on the detection of such changes in 15N/1H and/
or 13C/1H correlation spectra of a protein (or nucleic
acid) upon titration of a ligand or a mixture of ligands.
Chemical shift mapping can also provide crude struc-
tural information on the site of binding when the reso-
nance assignments are known. Nowadays, collection of
[15N, 1H] or [13C, 1H] correlations spectra (either TROSY-
type or conventional heteronuclear multiple quantum
correlation and heteronuclear single quantum correla-
tion) with uniformly or amino acid-type selectively la-
beled protein samples are the methods of choice [57–
65]. In analyzing chemical shift perturbation data, care
must be taken that long-range effects due to conforma-
tional changes are possible. In such cases, differential
chemical shift mapping by comparing spectra of com-
plexes between the target and two slightly different li-
gands have been proposed [59, 66, 67].
Measurements of chemical shift perturbation can
also be used to map interactions between macromole-
cules provided that a differential labeling can be engi-
neered (Figure 1A). In this approach, a protein domain
(or nucleic acid) is studied by NMR in the context of a
larger macromolecular complex. For example, the com-
plex between the molecular chaperone FimC and the
pilus subunit FimH (>50 kDa) could be studied by [15N,
1H]-TROSY experiments by using a sample containing
15N/2H-labeled FimC and unlabeled FimH (Figure 1B)
[68]. The surface of FimC interacting with FimH could
be mapped, and the binding site could be delineated.
When the X-ray structure of the complex was subse-
quently obtained [69], it confirmed the NMR-deter-
mined site of interaction between the two proteins (Fig-
ure 1B).
The use of chemical shift mapping to monitor ligand
binding has several major advantages. First, binders to
a given protein can be found without the need of de-
veloping a specific assay or even regardless of the
knowledge of its function. This is generally true for
most of the NMR-based techniques. In addition, given
that the resonance assignments are known, the loca-
tion of the site of binding can be obtained. Moreover, if
the structure of the target was previously determined
by NMR, in some instances it is possible to rapidly de-
rive intermolecular NOE-type constraints to precisely
locate the ligand on the protein binding site. The draw-
back of the chemical shift mapping is that the amount
of protein needed for a single NMR experiment has to
be relatively high for the technique to be used effi-
ciently to test large libraries of compounds. However,
we have to emphasize again that the technique is also
very sensitive to weak binding events, a fact that is
largely exploited in most of the NMR-based drug dis-
covery strategies. When such a weak binder (or pre-
ferred scaffold) is found to bind to a given protein, fol-
low-up hit optimizations strategies can be devised to
iteratively increase the affinity of the compound.A clever application of the chemical shift mapping isthe SAR (structure-activity relationships) by NMR strat-
egy [63, 65]. Here, a chemical shift mapping-based
screen for a second binder is performed in the pres-
ence of an initial weak hit (Figures 1C and 1D). Com-
pounds that induce chemical shift changes that corre-
spond to a region on the protein surface that is
adjacent to the site of binding of the first ligand are
considered. The structural characterization of the ter-
nary complex by NMR allows for the design of potential
chemical linkers between the compounds to afford a
more potent ligand, according the Equation 9:
KD
AB = KDA ∗ KDB ∗ E, (9)
where KDAB is the dissociation constant for the biden-
tate compound, KDA and KDB are the dissociation con-
stants of the individual initial binders, and E is the link-
ing coefficient [63]. In terms of free energy of binding:
GAB = HA + HB− TSAB = − RT ln KD AB, (10)
where R is the Boltzman constant, T is the temperature
of the system, HA and HB are the enthalpy of binding
of ligand A and ligand B, respectively, and SAB repre-
sents the entropy loss upon binding of the bidentate
compound. In an ideal case, this latter value could be
approximated to equal the loss of entropy of binding of
the isolated compounds (A or B). In other words, the
binding affinity of the bidentate compound is, in prin-
ciple, higher than that of the individual compounds be-
cause of a larger number of interactions (enthalpy fac-
tor), but also because of a reduced loss in entropy upon
binding. In practice, however, attaining perfectly rigid
linkers that allow for the simultaneous binding of A and
B is not always possible, and, inevitably, disturbance in
the binding of individual compounds can be introduced
by the linker itself. Nevertheless, the approach has
been demonstrated to yield bidentate compounds with
dramatically increased affinity with respect to the indi-
vidual fragments [63] (Figure 1D; see also Figure 4B and
“Transferred Effects”). In practical applications, initial
bidentate compounds represent the starting point for
traditional SAR-based optimizations to obtain even
more potent and selective compounds (for a recent ex-
ample, see [70]).
Transferred Effects
Let’s consider a system of two dipolarly coupled spins,
I and S (two hydrogen nuclei). The time evolution of the
longitudinal relaxation of the individual spins is given
by the Solomon equations [71]:
d<Iz>/dt = − ρI(<Iz> − Io) − σIS(<Sz> − So) (11)
d<Sz>/dt = − ρS(<Sz> − So) − σIS(<Iz> − Io). (12)
ρ and σIS represent the auto-relaxation and crossrelaxa-
tion rates, and Io, So, <Iz>, and <Sz> are the equilib-
rium and transient magnetization components of spins
I and S. Saturation of spin I, with <Iz> = 0, results in
the following expression for the steady-state situation
(d<Sz>/dt = 0):
<Sz> = So + (σIS/ρ)Io. (13)
Assuming that I and S are like spins (protons in most
applications), the saturation of I changes the intensity
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(A) Schematic representation of chemical shift mapping.
(B) The mapping of the pilus chaperone FimC (23 kDa, 15N/2H-labeled in 90:10 H2O:D2O buffer) for the pilus subunit FimH (28 kDa) monitored
via [15N, 1H]-TROSY (a region of the spectra is shown: red, bound; black, apo). The differences in chemical shifts between apo and bound
FimC are mapped on the 3D NMR structure of FimC (left) and are highlighted on the surface of FimC in orange (large shifts), yellow (smaller
shifts), and white (no shifts). Reproduced from [68]. As a comparison, on the right is reported the X-ray structure of the complex between
FimC (surface representation, in white) and FimH (ribbon representation). The area identified by the mapping strategy coincides with the
region of interaction that was later identified by X-ray crystallography.
(C and D) Schematic representation of the SAR by NMR approach and an example of a small bidentate molecule designed by using this
approach. Reproduced from [95].of the S resonance by (σIS/ρ) relative to the equilibrium
value, producing what is referred to as the “steady-
state NOE” [17].
The manifestation of the NOE is a function of the
nuclear spin crossrelaxation rates that are in turn linked
to the molecular correlation time. Small molecules tum-
ble very rapidly in solution, leading to positive NOEs:
the saturation of a nucleus induces a maximum relative
signal increase of w10% on adjacent nuclei. Macro-
molecules (or a small molecule bound to a macromole-
cule) tumble slowly, resulting in negative NOEs: the sat-
uration of a given nucleus results in a signal decrease
in adjacent nuclei, with a maximum effect of −100%.
Let’s introduce at this point an important consideration
about a small molecule binder at equilibrium with a
larger macromolecule. In analogy with slow and fast ex-
change in the chemical shift timescale discussed in the
previous paragraph, we can have slow or fast exchange
in the relaxation timescales. Slow exchange occurs
when the rate of equilibration, 1/τ, is slower than the
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bifference of the longitudinal and transverse relaxation
ates (denoted with R1 and R2, respectively) of the small
olecules in the free versus the bound state:
1 / τ << |(R2,TL) − R2,L)| and/or 1/τ
<< |(R1,TL) − R1,L)|. (14)
Likewise, fast exchange occurs if the rate of equili-
ration, 1/τ, is faster than the difference in relaxation
ates:
1 / τ >> |(R2,TL− R2,L)| and/or 1/τ >> |(R1,TL− R1,L)|.
(15)
An important consequence of Equation 15 is that, in
he fast exchange regime, the relaxation properties of
ligand at equilibrium with its complex with a macro-
olecular target is the weight average between the val-
es corresponding to the free and fully bound states.
In such situations (for ligands or macromolecular
inders in the low-micromolar to millimolar binding af-
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965finities), ligand binding can then be detected by meas-
uring the relaxation properties of the ligand in the pres-
ence of a substoichiometric amount of target.
In the saturation transfer difference (STD) experiment
[72, 73], a 1D steady-state NOE experiment is mea-
sured for a ligand in the presence of a small amount of
target, usually at a ligand:protein ratio of about 100:1.
As is illustrated in Figure 2A, when R1 (the longitudinal
relaxation rate for the proton nuclei of the small mole-
cule) is longer then the koff of the complex, there will be
an accumulation of saturated ligand if the target is also
present in a substoichiometric amount. The experiment
is based on a selective saturation of protein resonances
by irradiating regions of the 1H NMR spectrum (for ex-
ample the aliphatic region of the spectrum, between −1
and 2 ppm) that are usually not occupied by reso-
nances from small organic molecules. Subsequently, a
difference spectrum is generated from two spectra that
are recorded with and without preirradiation of protein
resonances. In the example reported in Figure 2, the
spectrum of the peptide PDTRP is recorded in the pres-
ence of the antibody SM3 with a presaturation of the
aliphatic region with a train of selective pulses. The dif-
ference spectrum can be obtained by comparison with
the same spectrum recorded by placing the train of
pulses well outside the spectral window of both the tar-
get and the small molecule (Figure 2B, red spectrum).
As a comparison, the 1D spectrum of the peptide isFigure 2. Monitoring Ligand-Protein Interac-
tions via Saturation Transfer Measurements
(A) Schematic representation of the satura-
tion transfer difference (STD) experiment.
(B) Example of a typical STD experiment il-
lustrating the spectrum of the peptide
PDTRP recorded in the presence of the anti-
body SM3 with a presaturation of the ali-
phatic region with a train of selective pulses.
The difference spectrum was obtained by
comparison with the same spectrum re-
corded by placing the irradiation well outside
the spectral window of both the target and
the small molecule (red spectrum). The 1D
spectrum of the peptide is also shown
(black), and the intensity is adjusted so that
the Pro1-β-methylene signal is the same
height in both spectra.
(C) Relative saturation of each resonance
line of the compound. This information can
be correlated to the mode of binding of a
given ligand. Reproduced from [74].also shown (Figure 2B, black spectrum), and the inten-
sity is adjusted so that the Pro1-β-methylene signal is
the same height in both spectra. Clearly visible is a
strong STD effect for protons of Pro1 and Asp2,
whereas the signals of Arg4 and Pro5 are less affected
by the saturation of the antibody resonances [74]. The
STD amplification factor (Equation 16) [75] is the frac-
tional saturation of a given proton multiplied by the ex-
cess of the ligand over the protein and was introduced
to allow for a better assessment of the absolute magni-
tude of the STD effect:
STD amplification factor
= (I0− Isat) / I0 × ligand excess. (16)
In Equation 16, (I0 − Isat)/I0 is the fractional STD effect,
expressing the signal intensity in the STD spectrum as
a fraction of the intensity of an unsaturated reference
spectrum.
The STD amplification factor provides an easy mea-
sure to quantify the amplification of the protein informa-
tion observed in the STD signals of the ligand and can
be used to compare the STD effect of the correspond-
ing resonances of the two molecules in the competition
or titration experiments, even if the protein concentra-
tion is not identical in the corresponding NMR samples.
From the relative saturation of the resonance lines
within a given binder (Figure 2C), the epitope of the in-
teractions can be obtained.
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Spectroscopy) is a related experiment in which the se-
lective saturation of the protein is achieved indirectly
by irradiation of water protons [76]; however, the exper-
iment is not suitable for epitope mapping.
As in the case of chemical shift mapping, transferred
effects could also be used to monitor macromolecular
interactions provided that a differential labeling scheme
could be obtained (Figure 3A). In an application that is
essentially similar to the STD approach described
above, the interaction between two proteins is moni-
tored by the acquisition of [15N, 1H]-TROSY NMR
spectra of a protein target, which is deuterated in all
nonexchangeable protons (Figure 3A). Two spectra are
recorded in the presence of a substoichiometric amount
of the second unlabeled protein (again, at about a 100:1
molar ratio), with and without saturation of the aliphatic
regions of the spectrum (Figures 3A and 3B) [77]. Be-
cause the second protein is unlabeled and the first one
is deuterated, the saturation of hydrogen nuclei in the
aliphatic region of the spectrum corresponds to a se-
lective saturation of the unlabeled protein. The satura-
tion is then transferred to the amide-protons of the in-
teracting protein via the NOE and is detected via
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(A) Schematic representation of the saturation transfer in the characterization of protein-protein interactions. One protein is labeled with 15N
and deuterated everywhere, except for the amides, which can be exchanged to protons in H2O buffer. The second protein is unlabeled.
Therefore, the saturation of the aliphatic region of the spectrum of a sample constituted by the two interacting proteins corresponds to a
selective saturation of the unlabeled protein.
(B) Example of mapping protein surfaces via saturation transfer. The intensity of crosspeaks in a [15N, 1H]-TROSY experiment measured with
15N/2H-labeled A3 domain in the presence of a small amount of immobilized collagen type III is measured with a presaturation centered at
the aliphatic region of the spectrum (therefore saturating collagen resonances) or outside the spectral region (as reference).
(C and D) The decrease of intensities between the two spectra is mapped into the 3D structure of the A3 domain and compared in (D) with
single point mutations that have been found to be important for binding to the A3 domain for collagen type III. Reproduced from [78].ROSY-NMR (Figures 3A and 3B). Provided that R1 (the
ongitudinal relaxation rate for the amide protons of the
abeled protein) is longer then the koff of the complex,
here will be an accumulation of saturated protein even
f the unlabeled partner protein is present in a sub-
toichiometric amount (Figures 3A and 3B). In the ex-
mple reported in Figure 3, this method was used to
ap the interactions between a 15N/2H-labeled A3 do-
ain and type III collagen [78]. The transfer of satura-
ion, when mapped into the 3D structure of the A3 do-
ain (Figure 3C), identifies residues that had been
reviously found by single point mutations to be impor-
ant for binding to the A3 domain for collagen type III,
s highlighted in Figure 3D.
Another example of a transferred experiment that can
e used to detect ligand binding is the 2D [1H, 1H]-
OESY spectrum. When measured for a small molecule
n the presence of a small amount of protein target, it
ives very strong negative intramolecular NOEs (diago-
al and crosspeaks will have the same sign) or very
mall positive NOEs (very weak crosspeaks of opposite
igns with respect to the diagonal peaks), depending
n whether the compound does or does not bind to the
arget, respectively.
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“transferred” effects because the relaxation effects in-
duced on the ligand by the target are transferred to the
free ligand [79].
In addition to intramolecular NOEs, the observation
of protein-mediated ligand-ligand NOEs (ILOEs) [53, 59,
60, 80–84] can be extremely informative in the design
of potential bidentate compounds and for lead optimi-
zation. Please note again that unlike direct, protein-
based NMR experiments, the ILOEs between adjacent
compounds are only mediated by the protein that is
therefore needed only in small amounts and unlabeled
(Figure 4A). Also, in this case, the size of the protein is
not a limiting factor. Even larger proteins are preferred
given that the ILOEs intensities are greater for slow-
tumbling molecules [53]. In an application we called
SAR by ILOEs, in analogy to the SAR by NMR method,
the design of potential bidentate compounds can be
achieved via detection of ILOEs in compound mixtures
[83]. To enhance the crossrelaxation rates of the bound
compounds, protein fusions can be used such as GST
fusion constructs [53]. These will have an artificially in-
creased molecular weight. In fact, when we used this
technique for smaller proteins (<15 kDa), the intensity
of the ILOE crosspeaks decreased dramatically. This
strategy can also be used to design selectivity, where
only fragments that uniquely bind (even weakly) to a
given protein target are used for lead optimization [80–
82]. In the example reported in Figure 4B, two weakly
binding compounds derived from fragmenting the com-
pound desthiobiotin (a ligand for the protein Avidin withFigure 4. Protein-Mediated Ligand-Ligand
Magnetization Transfer
(A) Schematic representation of the ligand-
ligand NOE experiment (ILOE). Provided that
R1A and R1B (the longitudinal relaxation rates
for the protons of both ligands) are longer
than their individual koff rates for the target,
ligand-ligand magnetization transfer can be
observed for the two ligands if also in the
presence of a substoichiometric amount of
protein target. For the ILOEs to be present,
the largest distance between the two pro-
tons, each on one of the proximal ligands,
should be <5 Å.
(B) Example of protein-mediated ligand-
ligand NOEs, between n-pentanoic acid and
4-methylimidazolidin-2-one, measured in the
presence of a substoichiometric amount of
Avidin. Ligand-ligand NOEs are indicated
with red circles. Reproduced from [80].picomolar affinity) display intramolecular and intermo-
lecular NOEs (ILOEs) in the presence of a substoichio-
metric amount of Avidin. Clearly, the potent binder des-
thiobiotin could have been designed based on the
observation of ligand-ligand NOEs between the two
fragments despite their low affinities (Figure 4), demon-
strating the power of the approach [80]. In another re-
cent example, we designed and synthesized a series of
compounds that binding to the surface of the proapo-
ptotic protein Bid, preventing its interactions with the
mitochondrial membrane [53]. This is an example of a
protein that could not have been easily targeted with
“conventional” screening techniques. Because high-
affinity ligands could in principle be designed and syn-
thesized against targets with unknown structure or
even less characterized function, this approach should
be very powerful not only in lead discovery and optimi-
zation projects, but also in reverse chemical-genetics
studies, in which the discovered high-affinity binders
can be used to determine the eventual phenotypic al-
terations that they induce in a cellular context [85].
Other Techniques
Fast exchange in the relaxation timescales also works
in enhancing the transverse relaxation times of a ligand
when in contact with a substoichiometric amount of
target. In a first application, ligand screening can be
achieved by measuring a 1D 1H NMR spectrum of the
ligand(s) with a relaxation filter (a spin-lock) in the pres-
ence and absence of a substoichiometric amount of
target. The relaxation filter has two functions: first, it
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Inhibition by NMR
(A) Schematic representation of the detec-
tion of enzyme kinetics by NMR.
(B) Measurements of protein kinase B activ-
ity by using a peptide of sequence CF3-CO-
ARKRERAYSFGHHA. The two peaks corre-
spond to the nonphosphorylated peptide
and the one in which the Ser residue is phos-
phorylated. Reproduced from [92].eliminates any residual signal from the target; second, it
enhances the differences in intensities between binders
and nonbinders. In typical applications, ligands can be
tested in mixtures at concentrations as low as 50 M,
and in the presence of a target concentration as low as
1 M [86]. Another approach to artificially enhance the
transverse relaxation of a ligand upon binding is to in-
troduce a paramagnetic spin on the target. If the target
contains a metal ion, the paramagnetic center could
simply be the metal ion itself (e.g., Mn2+) [59]. For other
targets, a paramagnetic spin can be artificially intro-
duced. A common spin label is 2,3,4,6-tetramethyl-
piperidine-1-oxyl (known as TEMPO) [87]. Finally, a sec-
ond site screen could be obtained by labeling the first
ligand with a spin label and using its relaxation en-
hancement effect to search for compounds that bind
on the surface of the target in proximity to the first
molecule. In analogy to the SAR by NMR and SAR by
ILOEs approaches, this strategy would lead to a pair of
compounds that occupy adjacent sites on the protein
surface. While the drawback of the method is that a
spin-labeled compound has to be obtained, the advan-
tage of this method is that the protein is simply mediat-
ing the interactions. Hence, only small amounts of unla-
beled target are needed, and the size of the target is
not a limiting factor [88].
Another recent application of NMR for screening
compounds makes use of an immobilized target [89].
In this approach, the immobilized protein is used to
capture binders that exhibit a reduced signal intensity
compared to a reference spectrum in which the ligand
is exposed to the matrix alone. The advantages of such
a technique over the transferred methods listed above
are that a single sample can be used several times and
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bhat even very strong binders (or those in slow ex-
hange on the relaxation and chemical shift timescales)
an be detected. An optimal use of this strategy is an-
icipated when combined with flow techniques [89].
onitoring Enzyme Kinetics and Inhibition by NMR
ssay miniaturization and the development of more
nd more sensitive and reliable readouts have made
he use of spectrophotometric assays the method of
hoice in detecting enzymatic activity. These methods
ave completely obscured one of the most obvious
ays in which to use NMR spectroscopy in the drug
iscovery process: monitoring enzyme kinetics and in-
ibition. There are several reported cases in which NMR
as found to be useful in specific applications; how-
ver, the application of general NMR-based enzymatic
ssays has remained sporadic until very recently, when
ore general applications to phosphatases, dehydrog-
nases, and two different classes of proteases have
een reported [53, 90–92] (Figure 5A). The simple ex-
erimental schemes take advantage of 31P and 19F
MR in appropriately labeled substrates or cofactors.
bservation of these nuclei offers two particular bene-
its: the large chemical shift dispersion and the high
ensitivity of the chemical shift to even small differ-
nces in the chemical environment. Also, because
hese nuclei are relatively uncommon biologically, the
bserved spectra will not suffer from overlap with other
ignals from the reaction buffers.
In Figure 5, we report an example of a clever assay
eveloped to detect enzyme kinetics and inhibition of
rotein kinase B by using a -CF3-labeled peptide sub-
trate [91]. The inhibition and the kinetic constants can
e easily measured in the NMR tube (Figure 5B).
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969Such assays could be very useful when dealing with
protein kinases [91], for example, where traditional as-
says for measuring phosphorylation of a reference pep-
tide require the use of specific antibodies or radioactive
ATP. Other cases in which having a simple NMR-based
assay is useful include the characterization of inhibitors
that may have an intrinsically high fluorescence or ab-
sorbance and, in fragment-based approaches, where
compounds are tested at high concentrations while
screening for preferential inhibitory scaffolds [53]. Small-
molecule compounds may have several unexpected ef-
fects on the assay components. Therefore, even for the
most reliable assays, having an orthogonal simple vali-
dation method such as the NMR assay is highly recom-
mended. For example, when dealing with potential
Caspase inhibitors [90], we have encountered com-
pounds that have high fluorescence that we could not
have reliably tested in the traditional fluorimetric assay.
Other compounds could show activity in the fluores-
cence-based assay simply by aggregating the sub-
strate peptide, a phenomenon that could simply be
detected in the NMR-based assay, given that both
cleaved and uncleaved substrates are observable.
A straightforward application of these types of as-
says is to monitor the inhibition propensities of small
libraries of scaffolds (or fragments), tested at high con-
centration. Subsequent follow-up optimizations can
follow the routes of medicinal chemistry and/or analog
selection, possibly aided by virtual docking of large li-
braries of compounds containing the selected scaffold
[53, 90]. Another recent example comes from our
laboratories in which a 19F-based assay was devised to
monitor the inhibitory properties of a small library of
scaffolds against the protease LF from B. anthracis. It-
erative optimizations of the initial micromolar inhibitor
lead to a potent and selective compound [93]. Another
powerful application of the NMR-based enzymatic as-
says occurs in functional screening projects, as re-
cently reported by Dalvit and coworkers [94].
Conclusions and Outlook
Current research efforts are focused on the discovery
and validation of novel potential drug targets. The com-
bination of bioinformatics, genome sequencing, and
structural biology initiatives can generate a number of
potential targets. NMR spectroscopy is a technique
that has been playing a significant role in the structural
elucidation of such protein targets, especially in the de-
termination of the structure of protein domains in solu-
tion. However, the use of differential labeling and the
advent of TROSY-type techniques have provided an ad-
ditional dimension for the use of NMR in the structural
biology field: the identification and characterization of
macromolecular interfaces. The early identification of
key interaction sites between macromolecular com-
plexes by using either direct or transferred NMR-based
approaches described above could rapidly provide in-
formation on possible targeting sites in the absence of
atomic resolution X-ray structures of the complex.
Moreover, NMR also has an important role in the study
and characterization of the interactions between small
organic molecules and macromolecular targets, and it
is particularly useful in lead identification and optimiza-tion processes. We anticipate a significant role of NMR-
based techniques in the near future, especially at the
early stages of target identification and validation and
in the development of small, organic molecules capable
of antagonizing complex macromolecular interactions.
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